Clinical data | |
---|---|
Trade names | Ixel, Joncia, Savella |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609016 |
Pregnancy category |
|
Routes of administration | By mouth (tablets), capsules) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 85% |
Protein binding | 13% |
Metabolism | Hepatic |
Elimination half-life | 8 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H22N2O |
Molar mass | 246.354 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Milnacipran (trade names Ixel, Savella, Dalcipran, Toledomin) is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia. It is not approved for the clinical treatment of major depressive disorder in the US, but it is in other countries.